본문 바로가기

LDR-Induced miR-30a and miR-30b Target the PAI-1 Pathway to Control Adverse Effects of NSCLC Radiotherapy

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
MOLECULAR THERAPY27(2) · pp.342 · 2019
피인용
Web of Science 30Scopus 33
FWCI (Scopus)
1.54
JCR IF
JCR 2018 8.402
ISSN
1525-0016

저자

  1. 박가을제1저자Department of Integrated Biological Science, Pusan National University, Busan, South Korea
  2. 손범석Department of Integrated Biological Science, Pusan National University, Busan, South Korea
  3. 강지훈Department of Integrated Biological Science, Pusan National University, Busan, South Korea
  4. 이성민Department of Integrated Biological Science, Pusan National University, Busan, South Korea
  5. 전재완Department of Integrated Biological Science, Pusan National University, Busan, South Korea
  6. Kim, Joo-HyungDepartment of Chemistry, Molecular Design Institute, New York University, New York, United States
  7. Yi, Gi-RaSchool of Chemical Engineering, Sungkyunkwan University (SKKU), Suwon, South Korea
  8. Youn, HyeSookDepartment of Integrative Bioscience and Biotechnology, Sejong University, Seoul, South Korea
  9. Moon, ChangjongDepartment of Veterinary Anatomy, College of Veterinary Medicine and BK21 Plus Project Team, Chonnam National University, Gwangju, South Korea
  10. Nam, Seon YoungLow-Dose Radiation Research Team, Radiation Health Institute, Korea Hydro & Nuclear Power Co., Ltd., Seoul, South Korea
  11. 윤부현교신저자Department of Biological Sciences, Pusan National University, Busan, South Korea

초록

Radiotherapy has been a central part in curing non-small cell lung cancer (NSCLC). However, it is possible that not all of the tumor cells are destroyed by radiation; therefore, it is important to effectively control residual tumor cells that could become aggressive and resistant to radiotherapy. In this study, we aimed to investigate the molecular mechanism of decreased NSCLC radioresistance by low-dose radiation (LDR) pretreatment. The results indicated that miR-30a and miR-30b, which effectively inhibited plasminogen activator inhibitor-1 (PAI-1), were overexpressed by treatment of LDR to NSCLC cells. Phosphorylation of Akt and ERK, the downstream survival signals of PAI-1, was decreased by PAI-1 inhibition. Reduced cell survival and epithelial-mesenchymal transition by PAI-1 inhibition were confirmed in NSCLC cells. Moreover, in vivo orthotopic xenograft mouse models with 7C1 nanoparticles to deliver miRNAs showed that tumor growth and aggressiveness were efficiently decreased by LDR treatment followed by radiotherapy. Taken together, the present study suggested that PAI-1, whose expression is regulated by LDR, was critical for controlling surviving tumor cells after radiotherapy.

키워드

EPITHELIAL-MESENCHYMAL TRANSITIONPLASMINOGEN-ACTIVATOR INHIBITOR-1CANCERRADIATIONMICRORNAINFLAMMATIONRECEPTORDELIVERYCELLSRADIORESISTANCE

식별자

Scopus EID
2-s2.0-85056258552
WoS UID
000457864300006